WO2017024317A3 - Methods to induce targeted protein degradation through bifunctional molecules - Google Patents

Methods to induce targeted protein degradation through bifunctional molecules Download PDF

Info

Publication number
WO2017024317A3
WO2017024317A3 PCT/US2016/046087 US2016046087W WO2017024317A3 WO 2017024317 A3 WO2017024317 A3 WO 2017024317A3 US 2016046087 W US2016046087 W US 2016046087W WO 2017024317 A3 WO2017024317 A3 WO 2017024317A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
protein degradation
targeted protein
bifunctional molecules
induce targeted
Prior art date
Application number
PCT/US2016/046087
Other languages
French (fr)
Other versions
WO2017024317A2 (en
Inventor
James Bradner
Dennis BUCKLEY
Georg Winter
Original Assignee
Dana-Farber Cancer Institute, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana-Farber Cancer Institute, Inc. filed Critical Dana-Farber Cancer Institute, Inc.
Publication of WO2017024317A2 publication Critical patent/WO2017024317A2/en
Publication of WO2017024317A3 publication Critical patent/WO2017024317A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/90—Isomerases (5.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y502/00—Cis-trans-isomerases (5.2)
    • C12Y502/01—Cis-trans-Isomerases (5.2.1)
    • C12Y502/01008—Peptidylprolyl isomerase (5.2.1.8), i.e. cyclophilin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/42—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a HA(hemagglutinin)-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]

Abstract

The present application provides bifunctional compounds which act as protein degradation inducing moieties. The present application also relates to nucleic acids, polypeptides, cells, and methods for highly regulated, targeted degradation of proteins through the use of the bifunctional compounds.
PCT/US2016/046087 2015-08-06 2016-08-08 Methods to induce targeted protein degradation through bifunctional molecules WO2017024317A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562202076P 2015-08-06 2015-08-06
US62/202,076 2015-08-06

Publications (2)

Publication Number Publication Date
WO2017024317A2 WO2017024317A2 (en) 2017-02-09
WO2017024317A3 true WO2017024317A3 (en) 2017-04-27

Family

ID=56990946

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2016/046087 WO2017024317A2 (en) 2015-08-06 2016-08-08 Methods to induce targeted protein degradation through bifunctional molecules

Country Status (1)

Country Link
WO (1) WO2017024317A2 (en)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107257800B (en) 2014-12-23 2020-06-30 达纳-法伯癌症研究所股份有限公司 Method for inducing target protein degradation by bifunctional molecules
US9694084B2 (en) 2014-12-23 2017-07-04 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
JP6817962B2 (en) * 2015-01-20 2021-01-20 アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． Compounds and methods for targeted androgen receptor degradation
US20170327469A1 (en) 2015-01-20 2017-11-16 Arvinas, Inc. Compounds and methods for the targeted degradation of androgen receptor
WO2017007612A1 (en) 2015-07-07 2017-01-12 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
WO2017030814A1 (en) 2015-08-19 2017-02-23 Arvinas, Inc. Compounds and methods for the targeted degradation of bromodomain-containing proteins
JP6968823B2 (en) 2016-04-22 2021-11-17 ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド Bifunctional molecule for degradation of EGFR, and how to use
CN109641874A (en) 2016-05-10 2019-04-16 C4医药公司 C for target protein degradation3The glutarimide degron body of carbon connection
WO2017197036A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
WO2017197055A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
WO2018064589A1 (en) 2016-09-29 2018-04-05 Dana-Farber Cancer Institute, Inc. Targeted protein degradation using a mutant e3 ubiquitin ligase
CN117510491A (en) 2016-12-23 2024-02-06 阿尔维纳斯运营股份有限公司 Compounds and methods for rapid accelerated targeted degradation of fibrosarcoma polypeptides
US11173211B2 (en) 2016-12-23 2021-11-16 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides
CN110769822A (en) 2017-06-20 2020-02-07 C4医药公司 N/O-linked degron and degron bodies for protein degradation
CN111278815B (en) 2017-09-04 2024-03-08 C4医药公司 Glutarimide
CN111278816B (en) 2017-09-04 2024-03-15 C4医药公司 Dihydro quinolinones
EP3679027A1 (en) 2017-09-04 2020-07-15 C4 Therapeutics, Inc. Dihydrobenzimidazolones
EP3700901A1 (en) 2017-10-24 2020-09-02 Genentech, Inc. (4-hydroxypyrrolidin-2-yl)-heterocyclic compounds and methods of use thereof
WO2019099868A2 (en) 2017-11-16 2019-05-23 C4 Therapeutics, Inc. Degraders and degrons for targeted protein degradation
AU2019225806A1 (en) * 2018-02-20 2020-07-16 Dana-Farber Cancer Institute, Inc. Inhibitors of EGFR and methods of use thereof
JP2021514012A (en) * 2018-02-20 2021-06-03 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Degradation inducer of EGFR and its usage
WO2019164932A1 (en) * 2018-02-20 2019-08-29 Dana-Farber Cancer Institute, Inc. Degraders of egfr and methods of use thereof
EP3755325A4 (en) * 2018-02-23 2022-03-02 Dana-Farber Cancer Institute, Inc. Small molecules for inducing selective protein degradation and uses thereof
JP2021519337A (en) 2018-03-26 2021-08-10 シー４ セラピューティクス， インコーポレイテッド Cereblon binder for the degradation of Ikaras
CN112312904A (en) 2018-04-16 2021-02-02 C4医药公司 Spiro compounds
JP7458324B2 (en) 2018-04-23 2024-03-29 セルジーン コーポレイション Substituted 4-aminoisoindoline-1,3-dione compounds and their use for the treatment of lymphoma
EP3578561A1 (en) 2018-06-04 2019-12-11 F. Hoffmann-La Roche AG Spiro compounds
WO2019238816A1 (en) 2018-06-13 2019-12-19 University Of Dundee Bifunctional molecules for targeting uchl5
WO2019238886A1 (en) 2018-06-13 2019-12-19 University Of Dundee Bifunctional molecules for targeting usp14
CN112533918A (en) 2018-06-13 2021-03-19 安菲斯塔治疗有限责任公司 Bifunctional molecules for targeting Rpn11
EP3817745A4 (en) * 2018-07-05 2022-04-06 Icahn School of Medicine at Mount Sinai Protein tyrosine kinase 6 (ptk6) degradation / disruption compounds and methods of use
JP7297053B2 (en) 2018-08-20 2023-06-23 アルビナス・オペレーションズ・インコーポレイテッド Alpha-Synuclein Protein-Targeted Proteolysis Targeting Chimeric (PROTAC) Compounds with E3 Ubiquitin Ligase Binding Activity to Treat Neurodegenerative Diseases
WO2020041387A1 (en) * 2018-08-20 2020-02-27 The Brigham And Women's Hospital, Inc. Degradation domain modifications for spatio-temporal control of rna-guided nucleases
CN111018857B (en) * 2018-10-09 2023-06-02 嘉兴优博生物技术有限公司 Targeted protease degradation platform (TED)
EP3864030A4 (en) * 2018-10-12 2022-09-21 The Scripps Research Institute Compounds and methods for dcaf-mediated protein degradation
CN113423701A (en) 2018-11-13 2021-09-21 拜欧斯瑞克斯公司 Substituted isoindolinones
WO2020146250A1 (en) * 2019-01-07 2020-07-16 Dana-Farber Cancer Institute, Inc. SMALL MOLECULE DEGRADERS OF FKBP12 VIA RECRUITMENT OF VON HIPPEL-LINDAU E3 UBIQUITIN LIGASE (VHL) E3 UBIQUITIN LIGASE, AND USES IN dTAG SYSTEMS
US20220135589A1 (en) * 2019-02-02 2022-05-05 Capc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. Targeted ubiquitination degradation brd4 protein compound, preparation method therefor and application thereof
WO2020163823A2 (en) * 2019-02-08 2020-08-13 University Of Florida Research Foundation, Incorporated Therapeutic agents and methods of treatment
MX2021011242A (en) 2019-03-21 2022-01-19 Codiak Biosciences Inc Extracellular vesicle conjugates and uses thereof.
US20220387906A1 (en) 2019-03-21 2022-12-08 Codiak Biosciences, Inc. Process for preparing extracellular vesicles
US20230093099A1 (en) * 2019-04-02 2023-03-23 Cullgen (Shanghai), Inc. Compounds and methods of treating cancers
EP3999182A1 (en) 2019-07-17 2022-05-25 Arvinas Operations, Inc. Tau-protein targeting compounds and associated methods of use
MX2022007659A (en) 2019-12-20 2022-07-19 C4 Therapeutics Inc Isoindolinone and indazole compounds for the degradation of egfr.
KR20220151160A (en) 2019-12-23 2022-11-14 카이메라 쎄라퓨틱스 인코포레이티드 SMARCA disintegrant and its uses
JP2023516073A (en) 2020-03-05 2023-04-17 シーフォー セラピューティクス， インコーポレイテッド Compounds for targeted degradation of BRD9
WO2021222138A1 (en) * 2020-04-27 2021-11-04 Development Center For Biotechnology Compounds for mutant ras protein degradation
WO2021237100A1 (en) 2020-05-21 2021-11-25 Codiak Biosciences, Inc. Methods of targeting extracellular vesicles to lung
WO2022066928A2 (en) 2020-09-23 2022-03-31 Codiak Biosciences, Inc. Process for preparing extracellular vesicles
CN116323570A (en) * 2020-09-30 2023-06-23 上海睿跃生物科技有限公司 Compounds and methods for treating diseases
CA3195448A1 (en) * 2020-10-14 2022-04-21 Weiwen Ying Methods and compositions for targeted protein degradation
TW202237095A (en) 2020-12-03 2022-10-01 德商艾斯巴赫生物有限公司 Alc1 inhibitors and synergy with parpi
WO2022125804A1 (en) * 2020-12-09 2022-06-16 Kymera Therapeutics, Inc. Smarca degraders and uses thereof
JP2024504932A (en) 2021-01-13 2024-02-02 モンテ ローザ セラピューティクス， インコーポレイテッド isoindolinone compound
WO2023283130A1 (en) 2021-07-04 2023-01-12 Newave Pharmaceutical Inc. Isoquinoline derivatives as mutant egfr modulators and uses thereof
AU2022317019A1 (en) * 2021-07-30 2024-02-29 Hinova Pharmaceuticals Inc. Bifunctional chimeric heterocyclic compound and use thereof as androgen receptor degrader
WO2023172889A1 (en) * 2022-03-07 2023-09-14 The University Of North Carolina At Chapel Hill Use of chemical epigenetic modifiers to modulate gene expression
WO2023213833A1 (en) 2022-05-02 2023-11-09 Eisbach Bio Gmbh Use of alc1 inhibitors and synergy with parpi
WO2023242176A1 (en) * 2022-06-13 2023-12-21 Julius-Maximilians-Universität Würzburg Transposase fusion proteins for use in cell and gene therapy

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003029827A2 (en) * 2001-10-01 2003-04-10 Bioimage A/S A method of detecting intracellular protein-protein interactions using three heterologous conjugates
WO2014159312A2 (en) * 2013-03-14 2014-10-02 University Of Florida Research Foundation, Incorporated A novel single chain antibody reduced mutant alpha-1 antitrypsin aggregation and toxicity
US20140335539A1 (en) * 2011-12-05 2014-11-13 Medical & Biological Laboratories Co., Ltd. Method for detecting protein-protein interaction

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4217344A (en) 1976-06-23 1980-08-12 L'oreal Compositions containing aqueous dispersions of lipid spheres
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4186183A (en) 1978-03-29 1980-01-29 The United States Of America As Represented By The Secretary Of The Army Liposome carriers in chemotherapy of leishmaniasis
US4261975A (en) 1979-09-19 1981-04-14 Merck & Co., Inc. Viral liposome particle
US4485054A (en) 1982-10-04 1984-11-27 Lipoderm Pharmaceuticals Limited Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV)
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4946787A (en) 1985-01-07 1990-08-07 Syntex (U.S.A.) Inc. N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5049386A (en) 1985-01-07 1991-09-17 Syntex (U.S.A.) Inc. N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US4774085A (en) 1985-07-09 1988-09-27 501 Board of Regents, Univ. of Texas Pharmaceutical administration systems containing a mixture of immunomodulators
DE3751873T2 (en) 1986-04-09 1997-02-13 Genzyme Corp Genetically transformed animals that secrete a desired protein in milk
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
AU7979491A (en) 1990-05-03 1991-11-27 Vical, Inc. Intracellular delivery of biologically active substances by means of self-assembling lipid complexes
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
US5587308A (en) 1992-06-02 1996-12-24 The United States Of America As Represented By The Department Of Health & Human Services Modified adeno-associated virus vector capable of expression from a novel promoter
US5994341A (en) 1993-07-19 1999-11-30 Angiogenesis Technologies, Inc. Anti-angiogenic Compositions and methods for the treatment of arthritis
US6231600B1 (en) 1995-02-22 2001-05-15 Scimed Life Systems, Inc. Stents with hybrid coating for medical devices
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
US5837313A (en) 1995-04-19 1998-11-17 Schneider (Usa) Inc Drug release stent coating process
ZA9710342B (en) 1996-11-25 1998-06-10 Alza Corp Directional drug delivery stent and method of use.
US6273913B1 (en) 1997-04-18 2001-08-14 Cordis Corporation Modified stent useful for delivery of drugs along stent strut
US5891507A (en) 1997-07-28 1999-04-06 Iowa-India Investments Company Limited Process for coating a surface of a metallic stent
US6153252A (en) 1998-06-30 2000-11-28 Ethicon, Inc. Process for coating stents
US6248127B1 (en) 1998-08-21 2001-06-19 Medtronic Ave, Inc. Thromboresistant coated medical device
US6534261B1 (en) 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US6258121B1 (en) 1999-07-02 2001-07-10 Scimed Life Systems, Inc. Stent coating
US6203551B1 (en) 1999-10-04 2001-03-20 Advanced Cardiovascular Systems, Inc. Chamber for applying therapeutic substances to an implant device
US6251136B1 (en) 1999-12-08 2001-06-26 Advanced Cardiovascular Systems, Inc. Method of layering a three-coated stent using pharmacological and polymeric agents
US6517889B1 (en) 2001-11-26 2003-02-11 Swaminathan Jayaraman Process for coating a surface of a stent
US9405700B2 (en) 2010-11-04 2016-08-02 Sonics, Inc. Methods and apparatus for virtualization in an integrated circuit
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003029827A2 (en) * 2001-10-01 2003-04-10 Bioimage A/S A method of detecting intracellular protein-protein interactions using three heterologous conjugates
US20140335539A1 (en) * 2011-12-05 2014-11-13 Medical & Biological Laboratories Co., Ltd. Method for detecting protein-protein interaction
WO2014159312A2 (en) * 2013-03-14 2014-10-02 University Of Florida Research Foundation, Incorporated A novel single chain antibody reduced mutant alpha-1 antitrypsin aggregation and toxicity

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
G. E. WINTER ET AL: "Phthalimide conjugation as a strategy for in vivo target protein degradation", SCIENCE, vol. 348, no. 6241, 19 June 2015 (2015-06-19), pages 1376 - 1381, XP055328122, ISSN: 0036-8075, DOI: 10.1126/science.aab1433 *
JAN KRÖNKE ET AL: "Lenalidomide induces ubiquitination and degradation of CK1[alpha] in del(5q) MDS", NATURE, vol. 523, no. 7559, 9 July 2015 (2015-07-09), United Kingdom, pages 183 - 188, XP055336278, ISSN: 0028-0836, DOI: 10.1038/nature14610 *
M. SEKIGUCHI ET AL: "An evaluation tool for FKBP12-dependent and -independent mTOR inhibitors using a combination of FKBP-mTOR fusion protein, DSC and NMR", PROTEIN ENGINEERING, DESIGN AND SELECTION, vol. 24, no. 11, 6 September 2011 (2011-09-06), GB, pages 811 - 817, XP055336205, ISSN: 1741-0126, DOI: 10.1093/protein/gzr045 *
PHILIP P CHAMBERLAIN ET AL: "Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs", NATURE STRUCTURAL AND MOLECULAR BIOLOGY, vol. 21, no. 9, 10 August 2014 (2014-08-10), US, pages 803 - 809, XP055336279, ISSN: 1545-9993, DOI: 10.1038/nsmb.2874 *
ROBERS MATT ET AL.: "Fluorescent labeling of proteins in living cells using the FKBP12 (F36V) tag", CYTOMETRY. PART A : THE JOURNAL OF THE INTERNATIONAL SOCIETY FOR ANALYTICAL CYTOLOGY, vol. 75, no. 3, March 2009 (2009-03-01), pages 207 - 224, XP002762671, ISSN: 1552-4930 *
WANG T ET AL: "Specific Interaction of Type I Receptors of the TGF-beta Family with the Immunophilin FKBP-12", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, vol. 265, 29 July 1994 (1994-07-29), pages 674 - 676, XP002173914, ISSN: 0036-8075, DOI: 10.1126/SCIENCE.7518616 *
WANG XIAO-SONG ET AL: "Characterization of KRAS rearrangements in metastatic prostate cancer", CANCER DISCOVERY,, vol. 1, no. 1, 1 June 2011 (2011-06-01), pages 35 - 43, XP009167682, ISSN: 2159-8290, DOI: 10.1158/2159-8274.CD-10-0022 *

Also Published As

Publication number Publication date
WO2017024317A2 (en) 2017-02-09

Similar Documents

Publication Publication Date Title
WO2017024317A3 (en) Methods to induce targeted protein degradation through bifunctional molecules
SA518400424B1 (en) Antibody molecules for cancer treatment
PH12018502361A1 (en) Gdf15 fusion proteins and uses thereof
TWI799368B (en) Anti-tl1a antigen binding proteins and related nucleic acids, expression vectors, host cells, pharmaceutical composition, methods and uses
WO2015109124A3 (en) Immunomodulatory agents
MX2019006045A (en) Psma targeting trispecific proteins and methods of use.
EP3741848A3 (en) Protease variants and polynucleotides encoding same
WO2015196128A3 (en) Alternative nucleic acid molecules and uses thereof
WO2016107818A8 (en) Compositions and methods for protein glycosylation
WO2015196130A3 (en) Alternative nucleic acid molecules and uses thereof
MX2017014908A (en) Trispecific binding proteins and methods of use.
EP3773727A4 (en) Bifunctional small molecules to target the selective degradation of circulating proteins
EP4219744A3 (en) Methods of preparing nucleic acids for sequencing
WO2018081592A3 (en) Compositions and methods for the production of compounds
WO2016066756A3 (en) Protease variants and polynucleotides encoding same
WO2016066757A3 (en) Protease variants and polynucleotides encoding same
EP3234200A4 (en) Compositions and methods for targeted depletion, enrichment, and partitioning of nucleic acids using crispr/cas system proteins
WO2015112886A3 (en) Binding proteins and methods of use thereof
MX2021010668A (en) Cytokine fusion proteins.
WO2015089511A3 (en) Modified nucleic acid molecules and uses thereof
WO2016065349A8 (en) Short non-coding protein regulatory rnas (sprrnas) and methods of use
BR112017016897A2 (en) fungal strains and methods of use
EA201790505A1 (en) CONNECTION, AIMED ON IL-23A AND TNF-ALPHA, AND ITS APPLICATION
EP3543335A3 (en) Soluble intein fusion proteins and methods for purifying biomolecules
EP3964575A3 (en) Alpha-amylase variants and polynucleotides encoding same

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16770585

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16770585

Country of ref document: EP

Kind code of ref document: A2